William Blair cut their FY2025 EPS estimates for Arhaus in a research note issued to investors on Wednesday, February 26th.

Fintel reports that on February 28, 2025, William Blair initiated coverage of Skye Bioscience (NasdaqGM:SKYE) with a ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of Altimmune (NasdaqGM:ALT) with a Market Perform ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of Corbus Pharmaceuticals Holdings (NasdaqCM:CRBP) ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of BioAge Labs (NasdaqGS:BIOA) with a Market ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of Structure Therapeutics Inc. - Depositary ...

We recently published a list of 8 Worst Performing Mutual Funds in 2024. In this article, we are going to take a look at ...

William Blair reiterated their market perform rating on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a report ...

In a report released today, Andy Hsieh from William Blair maintained a Hold rating on Altimmune (ALT – Research Report). The company’s shares ...

William Blair analyst Andy Hsieh initiated coverage of BioAge Labs (BIOA) with a Market Perform rating.Discover the Best Stocks and Maximize ...

William Blair analyst Jason Ader reiterated a Buy rating on Varonis Systems (VRNS – Research Report) today. The company’s shares opened today ...